309 related articles for article (PubMed ID: 35450750)
21. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
[TBL] [Abstract][Full Text] [Related]
22. In vivo relationship between near-infrared spectroscopy-detected lipid-rich plaques and morphological plaque characteristics by optical coherence tomography and intravascular ultrasound: a multimodality intravascular imaging study.
Zanchin C; Ueki Y; Losdat S; Fahrni G; Daemen J; Ondracek AS; Häner JD; Stortecky S; Otsuka T; Siontis GCM; Rigamonti F; Radu M; Spirk D; Kaiser C; Engstrom T; Lang I; Koskinas KC; Räber L
Eur Heart J Cardiovasc Imaging; 2021 Jun; 22(7):824-834. PubMed ID: 31990323
[TBL] [Abstract][Full Text] [Related]
23. 2017 Taiwan lipid guidelines for high risk patients.
Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
[TBL] [Abstract][Full Text] [Related]
24. Impact of Lipoprotein (a) on Long-Term Outcomes in Patients with Coronary Artery Disease Treated with Statin After a First Percutaneous Coronary Intervention.
Suwa S; Ogita M; Miyauchi K; Sonoda T; Konishi H; Tsuboi S; Wada H; Naito R; Dohi T; Kasai T; Okazaki S; Isoda K; Daida H
J Atheroscler Thromb; 2017 Nov; 24(11):1125-1131. PubMed ID: 28321012
[TBL] [Abstract][Full Text] [Related]
25. Low serum docosahexaenoic acid is associated with progression of coronary atherosclerosis in statin-treated patients with diabetes mellitus: results of the treatment with statin on atheroma regression evaluated by intravascular ultrasound with virtual histology (TRUTH) study.
Nozue T; Yamamoto S; Tohyama S; Fukui K; Umezawa S; Onishi Y; Kunishima T; Sato A; Nozato T; Miyake S; Takeyama Y; Morino Y; Yamauchi T; Muramatsu T; Hibi K; Terashima M; Michishita I
Cardiovasc Diabetol; 2014 Jan; 13():13. PubMed ID: 24410834
[TBL] [Abstract][Full Text] [Related]
26. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Emergency Complex Higher-risk and Indicated Patients.
Jin ZL; He T; Peng L; Wu XY; Fan D; Chen M; Fan YZ; Guo YL; Lu ZB; Wang HR
Curr Med Sci; 2023 Dec; 43(6):1206-1212. PubMed ID: 37755635
[TBL] [Abstract][Full Text] [Related]
27. Lower levels of low-density lipoprotein cholesterol are associated with a lower prevalence of thin-cap fibroatheroma in statin-treated patients with coronary artery disease.
Hashimoto T; Minami Y; Asakura K; Katamine M; Kato A; Katsura A; Sato T; Muramatsu Y; Kameda R; Meguro K; Shimohama T; Ako J
J Clin Lipidol; 2022; 16(1):104-111. PubMed ID: 34924352
[TBL] [Abstract][Full Text] [Related]
28. Relation of First and Total Recurrent Atherosclerotic Cardiovascular Disease Events to Increased Lipoprotein(a) Levels Among Statin Treated Adults With Cardiovascular Disease.
Wong ND; Zhao Y; Sung J; Browne A
Am J Cardiol; 2021 Apr; 145():12-17. PubMed ID: 33454339
[TBL] [Abstract][Full Text] [Related]
29. Effects of the PCSK9 antibody alirocumab on coronary atherosclerosis in patients with acute myocardial infarction: a serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study-Rationale and design of the PACMAN-AMI trial.
Zanchin C; Koskinas KC; Ueki Y; Losdat S; Häner JD; Bär S; Otsuka T; Inderkum A; Jensen MRJ; Lonborg J; Fahrni G; Ondracek AS; Daemen J; van Geuns RJ; Iglesias JF; Matter CM; Spirk D; Juni P; Mach F; Heg D; Engstrom T; Lang I; Windecker S; Räber L
Am Heart J; 2021 Aug; 238():33-44. PubMed ID: 33951415
[TBL] [Abstract][Full Text] [Related]
30. HDL
Chaudhary R; Kinderytė M; Chaudhary R; Sukhi A; Bliden K; Tantry U; Gurbel P
Cardiovasc Revasc Med; 2019 Nov; 20(11):1001-1006. PubMed ID: 30626544
[TBL] [Abstract][Full Text] [Related]
31. Remnant cholesterol, coronary atheroma progression and clinical events in statin-treated patients with coronary artery disease.
Elshazly MB; Mani P; Nissen S; Brennan DM; Clark D; Martin S; Jones SR; Quispe R; Donnellan E; Nicholls SJ; Puri R
Eur J Prev Cardiol; 2020 Jul; 27(10):1091-1100. PubMed ID: 31744333
[TBL] [Abstract][Full Text] [Related]
32. Effect of statin therapy on the progression of coronary atherosclerosis.
Tian J; Gu X; Sun Y; Ban X; Xiao Y; Hu S; Yu B
BMC Cardiovasc Disord; 2012 Sep; 12():70. PubMed ID: 22938176
[TBL] [Abstract][Full Text] [Related]
33. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
34. Association of Serum Lipoprotein (a) Levels and Coronary Atheroma Volume by Intravascular Ultrasound.
Huded CP; Shah NP; Puri R; Nicholls SJ; Wolski K; Nissen SE; Cho L
J Am Heart Assoc; 2020 Dec; 9(23):e018023. PubMed ID: 33222598
[TBL] [Abstract][Full Text] [Related]
35. [Effects of statins on coronary atherosclerotic plaque in patients with coronary heart disease and type 2 diabetes with mild elevated LDL-C].
Wang XF; Lu CZ; Chen X
Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Apr; 37(4):339-42. PubMed ID: 19791470
[TBL] [Abstract][Full Text] [Related]
36. Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN.
Puri R; Libby P; Nissen SE; Wolski K; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Raichlen JS; Uno K; Kataoka Y; Tuzcu EM; Nicholls SJ
Eur Heart J Cardiovasc Imaging; 2014 Apr; 15(4):380-8. PubMed ID: 24448227
[TBL] [Abstract][Full Text] [Related]
37. Identification of patients and plaques vulnerable to future coronary events with near-infrared spectroscopy intravascular ultrasound imaging: a prospective, cohort study.
Waksman R; Di Mario C; Torguson R; Ali ZA; Singh V; Skinner WH; Artis AK; Cate TT; Powers E; Kim C; Regar E; Wong SC; Lewis S; Wykrzykowska J; Dube S; Kazziha S; van der Ent M; Shah P; Craig PE; Zou Q; Kolm P; Brewer HB; Garcia-Garcia HM;
Lancet; 2019 Nov; 394(10209):1629-1637. PubMed ID: 31570255
[TBL] [Abstract][Full Text] [Related]
38. Residual Risk of Coronary Atherosclerotic Heart Disease and Severity of Coronary Atherosclerosis Assessed by ApoB and LDL-C in Participants With Statin Treatment: A Retrospective Cohort Study.
Yao T; Lu W; Ke J; Zhang H; Zhao X; Song B; Liu T; Ke Q; Liu C
Front Endocrinol (Lausanne); 2022; 13():865863. PubMed ID: 35573992
[TBL] [Abstract][Full Text] [Related]
39. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.
Nissen SE; Nicholls SJ; Sipahi I; Libby P; Raichlen JS; Ballantyne CM; Davignon J; Erbel R; Fruchart JC; Tardif JC; Schoenhagen P; Crowe T; Cain V; Wolski K; Goormastic M; Tuzcu EM;
JAMA; 2006 Apr; 295(13):1556-65. PubMed ID: 16533939
[TBL] [Abstract][Full Text] [Related]
40. Atheroma progression in hyporesponders to statin therapy.
Kataoka Y; St John J; Wolski K; Uno K; Puri R; Tuzcu EM; Nissen SE; Nicholls SJ
Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):990-5. PubMed ID: 25722430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
